PubAg

Main content area

Impact of Fusarium mycotoxins on hepatic and intestinal mRNA expression of cytochrome P450 enzymes and drug transporters, and on the pharmacokinetics of oral enrofloxacin in broiler chickens

Author:
Antonissen, Gunther, Devreese, Mathias, De Baere, Siegrid, Martel, An, Van Immerseel, Filip, Croubels, Siska
Source:
Food and chemical toxicology 2017 v.101 pp. 75-83
ISSN:
0278-6915
Subject:
European Union, Fusarium, absorption, broiler chickens, cytochrome P-450, deoxynivalenol, diet, drugs, enrofloxacin, enzymes, feed contamination, fumonisins, gene expression, jejunum, messenger RNA, multiple drug resistance, pharmacokinetics, quantitative polymerase chain reaction, reverse transcriptase polymerase chain reaction, toxicology, transporters
Abstract:
Cytochrome P450 (CYP450) drug biotransformation enzymes and multidrug resistance (MDR) proteins may influence drug disposition processes. The first part of the study aimed to evaluate the effect of mycotoxins deoxynivalenol (DON) and/or fumonisins (FBs), at contamination levels approaching European Union guidance levels, on intestinal and hepatic CYP450 enzymes and MDR proteins gene expression in broiler chickens. mRNA expression of genes encoding CYP450 enzymes (CYP3A37, CYP1A4 and CYP1A5) and drug transporters (MDR1/ABCB1 and MRP2/ABCC2) was determined using qRT-PCR. A significant up-regulation of CYP1A4 (P = 0.037) and MDR1 (P = 0.036) was observed in the jejunum of chickens fed a diet contaminated with FBs. The second part of this study aimed to investigate the impact of feeding a FBs contaminated diet on the oral absorption of enrofloxacin (10 mg/kg BW), a MDR1 substrate. A significant (P = 0.045), however small, decreased area under the plasma concentration-time curve (AUC0-48 h, mean ± SD) was observed for enrofloxacin in chickens fed the FBs contaminated diet compared to the control group, 16.28 ± 1.82 h μg/mL versus 18.27 ± 1.79 h μg/mL. These findings suggest that concurrent administration of drugs with FBs contaminated feed might alter the pharmacokinetic characteristics of CYP1A4 substrate drugs and MDR1 substrates, such as enrofloxacin.
Agid:
5618498